Clinical data | |
---|---|
Trade names | Lariam, Mephaquin, Mefliam, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a603030 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Extensive liver; main metabolite is inactive |
Elimination half-life | 2 to 4 weeks |
Excretion | Primarily bile and feces; urine (9% as unchanged drug, 4% as primary metabolite) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H16F6N2O |
Molar mass | 378.318 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
Mefloquine, sold under the brand name Lariam among others, is a medication used to prevent or treat malaria.[4] When used for prevention it is typically started before potential exposure and continued for several weeks after potential exposure.[4] It can be used to treat mild or moderate malaria but is not recommended for severe malaria.[4] It is taken by mouth.[4]
Common side effects include vomiting, diarrhea, headaches, sleep disorders, and a rash.[4] Serious side effects include potentially long-term mental health problems such as depression, hallucinations, and anxiety and neurological side effects such as poor balance, seizures, and ringing in the ears.[4] It is therefore not recommended in people with a history of mental health problems or epilepsy.[4] It appears to be safe during pregnancy and breastfeeding.[1]
Mefloquine was developed by the United States Army in the 1970s and came into use in the mid-1980s.[5][6][7] It is on the World Health Organization's List of Essential Medicines.[8][9] It is available as a generic medication.[4]